Does the media refer more to VKTX or ABUS?

In the previous week, Viking Therapeutics had 10 more articles in the media than Arbutus Biopharma. MarketBeat recorded 13 mentions for Viking Therapeutics and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Viking Therapeutics' score of 0.58 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, TLX or ABUS?

Telix Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.98 -$7.12M N/A N/A Arbutus Biopharma $14.08M 72.18 -$33.50M $0.79 6.49

Does the media refer more to TLX or ABUS?

In the previous week, Telix Pharmaceuticals had 14 more articles in the media than Arbutus Biopharma. MarketBeat recorded 17 mentions for Telix Pharmaceuticals and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Telix Pharmaceuticals' score of 0.17 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to IOVA or ABUS?

In the previous week, Iovance Biotherapeutics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Iovance Biotherapeutics and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Iovance Biotherapeutics' score of 1.40 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ABUS or AMLX?

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Amylyx Pharmaceuticals and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Amylyx Pharmaceuticals' score of 0.66 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABUS or TNGX?

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 3 articles in the media. Arbutus Biopharma's average media sentiment score of 1.76 beat Tango Therapeutics' score of 0.69 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arbutus Biopharma (ABUS) Competitors

$5.13 +0.01 (+0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$5.15 +0.02 (+0.45%)

As of 07:52 PM Eastern

Compare

ABUS vs. VKTX, TLX, IOVA, AMLX, and TNGX

Should you buy Arbutus Biopharma stock or one of its competitors? Arbutus Biopharma's main competitors and comparable companies include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arbutus Biopharma compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Arbutus Biopharma has a net margin of 84.22% compared to Viking Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Arbutus Biopharma	84.22%	90.98%	82.34%

In the previous week, Viking Therapeutics had 10 more articles in the media than Arbutus Biopharma. MarketBeat recorded 13 mentions for Viking Therapeutics and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Viking Therapeutics' score of 0.58 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Viking Therapeutics currently has a consensus target price of $96.63, indicating a potential upside of 206.45%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential downside of 2.53%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Arbutus Biopharma	$14.08M	72.18	-$33.50M	$0.79	6.49

Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Arbutus Biopharma beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Telix Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.98	-$7.12M	N/A	N/A
Arbutus Biopharma	$14.08M	72.18	-$33.50M	$0.79	6.49

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Arbutus Biopharma has a net margin of 84.22% compared to Telix Pharmaceuticals' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Arbutus Biopharma	84.22%	90.98%	82.34%

Telix Pharmaceuticals presently has a consensus price target of $20.40, indicating a potential upside of 73.17%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential downside of 2.53%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Telix Pharmaceuticals had 14 more articles in the media than Arbutus Biopharma. MarketBeat recorded 17 mentions for Telix Pharmaceuticals and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Telix Pharmaceuticals' score of 0.17 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Arbutus Biopharma beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Arbutus Biopharma has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	15.92	-$390.98M	-$0.73	N/A
Arbutus Biopharma	$14.08M	72.18	-$33.50M	$0.79	6.49

Arbutus Biopharma has a net margin of 84.22% compared to Iovance Biotherapeutics' net margin of -89.11%. Arbutus Biopharma's return on equity of 90.98% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Arbutus Biopharma	84.22%	90.98%	82.34%

Iovance Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Iovance Biotherapeutics and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Iovance Biotherapeutics' score of 1.40 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Iovance Biotherapeutics presently has a consensus price target of $8.89, indicating a potential downside of 4.01%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential downside of 2.53%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Arbutus Biopharma is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Arbutus Biopharma beats Iovance Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Amylyx Pharmaceuticals?

Arbutus Biopharma (NASDAQ:ABUS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Arbutus Biopharma has a net margin of 84.22% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Amylyx Pharmaceuticals and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Amylyx Pharmaceuticals' score of 0.66 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amylyx Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	72.18	-$33.50M	$0.79	6.49
Amylyx Pharmaceuticals	$87.37M	42.90	-$144.74M	-$1.43	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential downside of 2.53%. Amylyx Pharmaceuticals has a consensus price target of $36.50, suggesting a potential upside of 8.50%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Arbutus Biopharma beats Amylyx Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Tango Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Arbutus Biopharma has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arbutus Biopharma has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	72.18	-$33.50M	$0.79	6.49
Tango Therapeutics	$62.38M	66.33	-$101.59M	-$0.85	N/A

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential downside of 2.53%. Tango Therapeutics has a consensus price target of $43.46, suggesting a potential upside of 77.10%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Arbutus Biopharma has a net margin of 84.22% compared to Tango Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Tango Therapeutics	N/A	-25.75%	-23.36%

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 3 articles in the media. Arbutus Biopharma's average media sentiment score of 1.76 beat Tango Therapeutics' score of 0.69 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arbutus Biopharma beats Tango Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.86B	$7.15B	$13.98B
Dividend Yield	N/A	3.66%	2.57%	11.70%
P/E Ratio	6.49	14.33	272.99	25.37
Price / Sales	72.18	1,295.87	602.82	70.35
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	12.83	15.26	10.43	6.24
Net Income	-$33.50M	-$22.78M	$3.49B	$358.08M
7 Day Performance	-0.39%	-2.03%	-2.11%	-1.43%
1 Month Performance	9.85%	2.10%	0.64%	-2.71%
1 Year Performance	15.02%	42.58%	24.61%	8.46%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	1.582 of 5 stars	$5.13 +0.2%	$5.00 -2.5%	+14.8%	$1.01B	$14.08M	6.49	19	Positive News
VKTX Viking Therapeutics	2.9086 of 5 stars	$34.87 flat	$96.63 +177.1%	+28.9%	$4.07B	N/A	N/A	20	Positive News
TLX Telix Pharmaceuticals	3.7561 of 5 stars	$11.94 flat	$20.40 +70.9%	+22.6%	$4.06B	$803.79M	N/A	1,184	Trending News Analyst Forecast Gap Up
IOVA Iovance Biotherapeutics	1.6499 of 5 stars	$8.79 flat	$8.89 +1.1%	+278.9%	$3.98B	$263.50M	N/A	500	Positive News
AMLX Amylyx Pharmaceuticals	3.4899 of 5 stars	$34.10 flat	$36.50 +7.0%	+171.4%	$3.80B	$87.37M	N/A	200	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. VKTX, TLX, IOVA, AMLX, and TNGX

How does Arbutus Biopharma compare to Viking Therapeutics?

Summary

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Summary

How does Arbutus Biopharma compare to Iovance Biotherapeutics?

Summary

How does Arbutus Biopharma compare to Amylyx Pharmaceuticals?

Summary

How does Arbutus Biopharma compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. VKTX, TLX, IOVA, AMLX, and TNGX

How does Arbutus Biopharma compare to Viking Therapeutics?

Is VKTX or ABUS more profitable?

Does the media refer more to VKTX or ABUS?

Do analysts rate VKTX or ABUS?

Which has higher earnings and valuation, VKTX or ABUS?

Which has more risk & volatility, VKTX or ABUS?

Do insiders & institutionals believe in VKTX or ABUS?

Summary

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Which has preferable valuation and earnings, TLX or ABUS?

Do institutionals and insiders believe in TLX or ABUS?

Which has more volatility & risk, TLX or ABUS?

Is TLX or ABUS more profitable?

Do analysts rate TLX or ABUS?

Does the media refer more to TLX or ABUS?

Summary

How does Arbutus Biopharma compare to Iovance Biotherapeutics?

Which has better valuation and earnings, IOVA or ABUS?

Is IOVA or ABUS more profitable?

Which has more risk and volatility, IOVA or ABUS?

Does the media refer more to IOVA or ABUS?

Do analysts prefer IOVA or ABUS?

Do insiders & institutionals believe in IOVA or ABUS?

Summary

How does Arbutus Biopharma compare to Amylyx Pharmaceuticals?

Which has more volatility & risk, ABUS or AMLX?

Is ABUS or AMLX more profitable?

Does the media favor ABUS or AMLX?

Which has better valuation & earnings, ABUS or AMLX?

Do insiders & institutionals hold more shares of ABUS or AMLX?

Do analysts prefer ABUS or AMLX?

Summary

How does Arbutus Biopharma compare to Tango Therapeutics?

Which has more volatility & risk, ABUS or TNGX?

Do insiders and institutionals hold more shares of ABUS or TNGX?

Which has better valuation and earnings, ABUS or TNGX?

Do analysts recommend ABUS or TNGX?

Is ABUS or TNGX more profitable?

Does the media favor ABUS or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools